研究実績  |  RESULTS ACHIEVEMENT

英文論文

    2019
  • Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, Hirohama D, Kawakami-Mori F, Shibata S, Nagase M, Isshiki M, Oba S, Shimosawa T, Fujita T. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study. Hypertens Res. 2019 Apr;42(4):514-521.

  • 2019
  • Takita M, Jimbo E, Fukui T, Aida K, Shimada A, Oikawa Y, Yagihashi S, Miura J, Babazono T, Kobayashi T. Unique Inflammatory Changes in Exocrine and Endocrine Pancreas in Enterovirus-induced Fulminant Type 1 Diabetes. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4282-429.

  • 2019
  • Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T; consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019 Jan;10(1):58-66.

  • 2018
  • Mizutani G, Hikima Y, Satomura A, Iuchi T, Nakajima R, Miyashita Y, Yasuda S, Oikawa Y, Isshiki M, Inoue I, Noda M, Shimada A: Administration of thiamazole for Graves’ disease might trigger the onset of type  1 diabetes. J Diabetes Investig 9:1228-1229,2018

  • 2018
  • Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A: Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in ‘anti-programmed cell death protein 1 antibody-induced’ fulminant type 1 diabetes. J Diabetes Investig 9:448-449,2018

  • 2018
  • Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina A, Shiki K, George J, Soleymanlou N, Marquard J: Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. Diabetes Obes Metab 20:2190-2199,2018

  • 2018
  • Ikegami Y, Inoue I, Inoue K, Shinoda Y, Iida S, Goto S, Nakano T, Shimada A, Noda M: The annual rate of coronary artery calcification with combination therapy with a  PCSK9 inhibitor and a statin is lower than that with statin monotherapy. NPJ Aging Mech Dis 4:7,2018

  • 2018
  • Ito D, Inoue K, Sumita T, Hamaguchi K, Kaneko K, Yanagisawa M, Inukai K, Inoue I, Noda M, Shimada A: Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in  Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study. J Clin Med Res 10:679-687, 2018

  • 2018
  • Nishimoto M, Mizuno R, Fujita T, Isshiki M: Stromal interaction molecule 1 modulates blood pressure via NO production in vascular endothelial cells. Hypertens Res 41:506-514,2018

  • 2018
  • Kondo Y, Goto A, Noma H, Iso H, Hayashi K, Noda M: Effects of Coffee and Tea Consumption on Glucose Metabolism: A Systematic Review  and Network Meta-Analysis. Nutrients 11: pii: E48, 2018

  • 2018
  • Tokunaga A, Imagawa A, Nishio H, Hayata S, Shimomura I, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T: Diffusion-weighted magnetic resonance imaging in the pancreas of fulminant type 1 diabetes. Diabetol Int 9:257-265,2018

  • 2018
  • Kanozawa K, Noguchi Y, Sugahara S, Nakamura S, Yamamoto H, Kaneko K, Kono R, Sato S, Ogawa T, Hasegawa H, Katayama S. The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial. Clin Exp Nephrol. 2018 Aug;22(4):825-834.

  • 2018
  • Uchida J, Oikawa Y, Katsuki T, Takeda H, Shimada A, Kawai T: Insulin degludec overdose may lead to long-lasting hypoglycaemia through its markedly prolonged half-life. Diabet Med 35:277-280,2018

  • 2018
  • Katayama S, Hatano M, Issiki M. Clinical features and therapeutic perspectives on hypertension in diabetics. Hypertens Res. 2018;41(4):213-229.

  • 2018
  • Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T; consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2018 Jul 3;10(1):58-66. 

  • 2018
  • Tonoike M, Chujo D, Noda M. Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes. Endocrinol Diabetes Metab. 2018 Nov 2;2(1):e00043. 

  • 2018
  • Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. Japanese Clinical Practice Guideline for Diabetes 2016. Diabetol Int. 2018 Mar 27;9(1):1-45.

  • 2018
  • Yamamoto-Honda R, Takahashi Y, Mori Y, Yamashita S, Yoshida Y, Kawazu S, Iwamoto Y, Kajio H, Yanai H, Mishima S, Handa N, Shimokawa K, Yoshida A, Watanabe H, Ohe K, Shimbo T, Noda M: Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03). Intern Med 57:1229-1240,2018

  • 2018
  • Imai H, Furukawa TA, Hayashi SU, Goto A, Izumi K, Hayashino Y, Noda M: Risk perception, self-efficacy, trust for physician, depression, and behavior modification in diabetic patients. J Health Psychol 1359105317718057,2018

  • 2018
  • Kurozumi A, Okada Y, Satoh H, Inoue I, Chimori H, Akita E, Shiraiwa T, Fujitani Y, Mita T, Gosho M, Watada H: Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects  on postprandial blood glucose (L-STEP) sub-study 1. Endocr J 65:415-425,2018

  • 2018
  • Goto A, Noda M, Goto M, Yasuda K, Mizoue T, Yamaji T, Sawada N, Iwasaki M, Inoue M, Tsugane S: Predictive performance of a genetic risk score using 11 susceptibility alleles for the incidence of Type 2 diabetes in a general Japanese population: a nested case-control study. Diabet Med 35:602-611,2018

  • 2018
  • Narita S, Saito E, Sawada N, Shimazu T, Yamaji T, Iwasaki M, Sasazuki S, Noda M, Inoue M, Tsugane S: Coffee Consumption and Lung Cancer Risk: The Japan Public Health Center-Based Prospective Study. J Epidemiol 28:207-213,2018

  • 2018
  • Takenaka Y, Inoue I, Nakano T, Ikeda M, Kakinuma Y, Ikegami Y, Shimada A, Noda M: Evaluation of Teneligliptin Effects on Transcriptional Activity of PPARgamma in Cell-Based Assays. J Nippon Med Sch 85:95-101,2018

  • 2018
  • Kurotani K, Karunapema P, Jayaratne K, Sato M, Hayashi T, Kajio H, Fukuda S, Hara H, Okazaki O, Jayatilleke AU, Nonaka D, Noda M, Mizoue T: Circulating odd-chain saturated fatty acids were associated with arteriosclerosis among patients with diabetes, dyslipidemia, or hypertension in Sri Lanka but not  Japan. Nutr Res 50:82-93,2018

  • 2018
  • Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E: Japanese Clinical Practice Guideline for Diabetes 2016. J Diabetes Investig,2018

  • 2018
  • Kaburagi Y, Takahashi E, Kajio H, Yamashita S, Yamamoto-Honda R, Shiga T, Okumura A, Goto A, Fukazawa Y, Seki N, Tobe K, Matsumoto M, Noda M, Unoki-Kubota H: Urinary afamin levels are associated with the progression of diabetic nephropathy. Diabetes Res Clin Pract 147:37-46,2018

  • 2018
  • Mori N, Shimazu T, Charvat H, Mutoh M, Sawada N, Iwasaki M, Yamaji T, Inoue M, Goto A, Takachi R, Ishihara J, Noda M, Iso H, Tsugane S: Cruciferous vegetable intake and mortality in middle-aged adults: A prospective cohort study. Clin Nutr ,2018

  • 2018
  • Koshi T, Sagesaka H, Sato Y, Hirabayashi K, Koike H, Yamauchi K, Nishimura R, Noda M, Yamashita K, Aizawa T: Elevated haemoglobin A1c but not fasting plasma glucose conveys risk of chronic kidney disease in non-diabetic individuals. Diabetes Res Clin Pract 146:233-239,2018

  • 2018
  • Ihira H, Sawada N, Iwasaki M, Yamaji T, Goto A, Noda M, Iso H, Tsugane S: Adult height and all-cause and cause-specific mortality in the Japan Public Health Center-based Prospective Study (JPHC). PLoS One 13:e0197164,2018

  • 2018
  • Aida K, Fukui T, Jimbo E, Yagihashi S, Shimada A, Oikawa Y, Mori Y, Fujii T, Nishida Y, Koyama R, Kobayashi T: Distinct Inflammatory Changes of the Pancreas of Slowly Progressive Insulin-dependent (Type 1) Diabetes. Pancreas 47:1101-1109, 2018

ACCESSご案内

埼玉医科大学

埼玉医科大学病院

〒350-0495 埼玉県入間郡毛呂山町毛呂本郷38
TEL: 049-276-1111(代)
FAX: 049-294-9752

お車をご利用される方
鶴ヶ島インターから約10km(約20~30分)
詳しくはこちら

電車・バスをご利用される方
池袋駅より東毛呂駅まで約1時間
東毛呂駅からバス(約5分)もしくは徒歩(約20分)
詳しくはこちら

本フォームは医療従事者専用となっております。ご病状やお薬、検査、予約など診療に関する患者さんからのご相談は、法律上、一切お受けすることができません。ご理解のほどよろしくお願いいたします。